Clinical Trial Update: Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel) [Phase 1]

View source ↗

Summary

Phase 1 safety trial of Ciliary Neurotrophic Factor (CNTF) in patients with macular telangiectasia completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Juxtafoveal Telangiectasia
• Macular Telangiectasia Type

Drugs mentioned

• CNTF (Ciliary Neurotrophic Factor) (ciliary neurotrophic factor)

Snippet

Sponsor: Neurotech Pharmaceuticals | Conditions: Idiopathic Juxtafoveal Telangiectasia | Phase 1 | Status: COMPLETED